{"id":"https://openalex.org/W417333223","doi":"https://doi.org/10.1182/blood.v124.21.5472.5472","title":"Clinical Pharmacokinetic (PK) and Safety (Immunogenicity) of Rituximab Biosimilar RTXM83 in Combination with Chemotherapy CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)","display_name":"Clinical Pharmacokinetic (PK) and Safety (Immunogenicity) of Rituximab Biosimilar RTXM83 in Combination with Chemotherapy CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W417333223","doi":"https://doi.org/10.1182/blood.v124.21.5472.5472","mag":"417333223"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.5472.5472","doi":"https://doi.org/10.1182/blood.v124.21.5472.5472","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.5472.5472","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008474298","display_name":"Amalia Florez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267846","display_name":"mAbxience Holding, S.L. (Spain)","ror":"https://ror.org/04pwqs835","country_code":"ES","type":"company","lineage":["https://openalex.org/I4405267846"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Amalia Florez","raw_affiliation_strings":["MAbxience, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MAbxience, Madrid, Spain","institution_ids":["https://openalex.org/I4405267846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014407097","display_name":"Thiago Di Matteo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267846","display_name":"mAbxience Holding, S.L. (Spain)","ror":"https://ror.org/04pwqs835","country_code":"ES","type":"company","lineage":["https://openalex.org/I4405267846"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Thiago Di Matteo","raw_affiliation_strings":["MAbxience, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MAbxience, Madrid, Spain","institution_ids":["https://openalex.org/I4405267846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010536935","display_name":"Gloria Fresnillo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267846","display_name":"mAbxience Holding, S.L. (Spain)","ror":"https://ror.org/04pwqs835","country_code":"ES","type":"company","lineage":["https://openalex.org/I4405267846"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Gloria Fresnillo","raw_affiliation_strings":["MAbxience, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MAbxience, Madrid, Spain","institution_ids":["https://openalex.org/I4405267846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054978819","display_name":"Consuelo Tudela","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267846","display_name":"mAbxience Holding, S.L. (Spain)","ror":"https://ror.org/04pwqs835","country_code":"ES","type":"company","lineage":["https://openalex.org/I4405267846"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Consuelo Tudela","raw_affiliation_strings":["MAbxience, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MAbxience, Madrid, Spain","institution_ids":["https://openalex.org/I4405267846"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041332517","display_name":"Mauricio Angel Seigelchifer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mauricio Seigelchifer","raw_affiliation_strings":["Pharmadn, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmadn, Buenos Aires, Argentina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047284502","display_name":"Esteban Corley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Esteban Corley","raw_affiliation_strings":["Pharmadn, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmadn, Buenos Aires, Argentina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045835831","display_name":"Anal\u00eda Pesce","orcid":"https://orcid.org/0000-0001-8539-8318","observed_orcids":["https://orcid.org/0000-0001-8539-8318"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Analia Pesce","raw_affiliation_strings":["Pharmadn, Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmadn, Buenos Aires, Argentina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067958630","display_name":"C\u00e9dric B\u00e8s","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267846","display_name":"mAbxience Holding, S.L. (Spain)","ror":"https://ror.org/04pwqs835","country_code":"ES","type":"company","lineage":["https://openalex.org/I4405267846"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Cedric Bes","raw_affiliation_strings":["MAbxience, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MAbxience, Madrid, Spain","institution_ids":["https://openalex.org/I4405267846"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113777774","display_name":"Susana Mill\u00e1n","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267846","display_name":"mAbxience Holding, S.L. (Spain)","ror":"https://ror.org/04pwqs835","country_code":"ES","type":"company","lineage":["https://openalex.org/I4405267846"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Susana Millan","raw_affiliation_strings":["MAbxience, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MAbxience, Madrid, Spain","institution_ids":["https://openalex.org/I4405267846"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.5492,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.6198933,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"124","issue":"21","first_page":"5472","last_page":"5472"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.7544000148773193,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.7544000148773193,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.23270000517368317,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab-biosimilar","display_name":"rituximab biosimilar","score":0.9779999852180481},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.8450000286102295},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.8840000033378601},{"id":"https://openalex.org/keywords/r-chop","display_name":"R-CHOP","score":0.8510000109672546},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8629999756813049},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9810000061988831},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.746999979019165},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.39899998903274536},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.546999990940094},{"id":"https://openalex.org/keywords/biosimilarity","display_name":"biosimilarity","score":0.5049999952316284},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.6679999828338623},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.8930000066757202},{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.9419999718666077},{"id":"https://openalex.org/keywords/prednisolone","display_name":"prednisolone","score":0.9850000143051147}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8113312721252441},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7398470044136047},{"id":"https://openalex.org/C2779725641","wikidata":"https://www.wikidata.org/wiki/Q1076228","display_name":"CHOP","level":3,"score":0.5964577198028564},{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.5905876159667969},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5320606827735901},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.5188990235328674},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4867362976074219},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4831959009170532},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45721977949142456},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.43134674429893494},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4200686514377594},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38492411375045776}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.5472.5472","doi":"https://doi.org/10.1182/blood.v124.21.5472.5472","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.5472.5472","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2954018422","https://openalex.org/W2527525726","https://openalex.org/W2891887641","https://openalex.org/W2225119936","https://openalex.org/W4310124581","https://openalex.org/W4399299700","https://openalex.org/W2596496142","https://openalex.org/W2998910020","https://openalex.org/W2992331654","https://openalex.org/W2987852851"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"RTXM83":[2,22,102,252,349,425,465],"is":[3,32,51,64,466],"a":[4,94,138,169,238,257,283,310,374],"rituximab":[5,414,441],"biosimilar":[6],"candidate":[7],"manufactured":[8],"by":[9,28],"MAbxience":[10],"Company.":[11],"Full":[12],"spectrum":[13],"of":[14,21,70,79,115,137,171,210,219,246,343,345,369,382,392,440,464,477],"physicochemical":[15],"and":[16,23,41,47,88,103,122,146,156,189,215,240,253,260,273,282,335,364,399,426,461],"preclinical":[17],"studies":[18],"showed":[19],"biosimilarity":[20],"originator":[24],"drug":[25],"MabThera\u00ae/Rituxan\u00ae":[26,30],"marketed":[27],"Roche.":[29],"product":[31],"approved":[33,52],"to":[34,53,92,100,109,142,161,303,306,479],"treat":[35,54],"Non-Hodgkin\u00b4s":[36],"Lymphoma,":[37],"chronic":[38],"lymphocytic":[39],"leukemia":[40],"rheumatoid":[42],"arthritis":[43],"in":[44,60,76,227,270,286,309,357,361,373,415,470],"the":[45,61,80,144,202,211,279,287,324,341],"EU":[46],"US,":[48],"plus":[49],"it":[50],"Diffuse":[55],"Large":[56],"B-cell":[57],"lymphoma":[58,71],"(DLBCL)":[59],"EU.":[62],"Rituximab":[63,204,370,393],"also":[65],"used":[66],"for":[67,168,186,243,413,456],"other":[68,416],"types":[69],"(e.g.":[72],"Mantle":[73],"cell":[74],"lymphoma)":[75],"certain":[77],"parts":[78],"word.":[81],"Objective:":[82],"To":[83],"demonstrate":[84],"comparable":[85,408,451,467],"pharmacokinetics":[86],"(PK)":[87],"safety":[89],"profile":[90,460,463],"(immunogenicity)":[91],"MabThera\u00ae,":[93],"clinical":[95,325],"PK/immunogenicity":[96],"analysis":[97,176],"was":[98,163,264,422],"designed":[99],"compare":[101],"MabThera\u00ae":[104,351,427],"when":[105],"administered":[106,356],"with":[107,111,128,133,359,409,452,468],"CHOP":[108,360],"patients":[110,127,401],"DLBCL.":[112,472],"Methods:":[113],"Analysis":[114],"an":[116,247],"interim":[117],"PK/Safety":[118],"report":[119],"from":[120,201],"randomized":[121],"blinded":[123],"study,":[124],"where":[125],"24":[126],"newly":[129],"diagnosed":[130],"DLBCL":[131],"treated":[132],"R-CHOP":[134,148],"as":[135,266],"part":[136,277],"multi-center":[139],"study":[140,220,288],"undertaken":[141],"assess":[143],"PK":[145,175,197,383,459],"immunogenicity.":[147,432],"(rituximab-375mg/m2;":[149],"cyclophopsphamide-750mg/m2;":[150],"adriamycin-50mg/m2;":[151],"vincristine-1.4mg/m2":[152],"on":[153,158,179,237,330],"day":[154],"1":[155,160,188,363],"prednisolone-60mg/m2":[157],"days":[159],"5)":[162],"given":[164],"every":[165],"3":[166],"weeks":[167],"total":[170],"6":[172,191,334,398],"cycles.":[173,447],"The":[174,232,378,434],"were":[177,199,235,328,402,443],"conducted":[178],"quality":[180],"control":[181],"(QC)":[182],"checked":[183],"analytical":[184],"data":[185,406,435,449],"Cycle":[187,190,331,333,362,365],"using":[192,224],"nominal":[193],"blood":[194],"sampling":[195],"times.":[196],"parameters":[198,384],"determined":[200],"serum":[203,367],"concentration-time":[205],"profiles":[206],"obtained":[207],"following":[208],"administration":[209],"first":[212],"(Cycle":[213,222],"1)":[214],"last":[216],"intravenous":[217],"infusion":[218,344],"medication":[221],"6)":[223],"non-compartmental":[225],"procedures":[226],"Phoenix":[228],"WinNonlin":[229],"(Version":[230],"6.2.1).":[231],"immunogenicity":[233,326,462],"assessments":[234],"based":[236],"specific":[239,261],"validated":[241],"method":[242],"systematic":[244],"evaluation":[245],"unwanted":[248],"immune":[249],"response":[250],"against":[251],"MabThera\u00ae.":[254],"In":[255],"fact,":[256],"confirmatory":[258,311],"assay":[259,280,293,313],"cut":[262],"point":[263],"established":[265],"current":[267],"described":[268],"recommendations":[269],"white":[271],"papers":[272],"guidance":[274],"documents.":[275],"This":[276],"assures":[278],"sensitivity":[281],"\u201ccharacterization":[284],"step\u201d":[285],"sample":[289],"analysis.":[290],"A":[291],"screening":[292],"that":[294,299,316,437],"picks":[295],"up":[296],"5%":[297],"positives":[298,319],"are":[300,407,450],"subsequently":[301],"shown":[302],"be":[304,321],"due":[305],"non-specific":[307],"binding":[308],"(immunodepletion)":[312],"provides":[314],"assurance":[315],"true":[317],"low":[318],"can":[320],"detected.":[322],"Finally,":[323],"measurements":[327],"performed":[329],"5,":[332],"follow-up":[336,400],"patient":[337],"samples.":[338],"Results:":[339],"Following":[340],"end":[342],"375":[346],"mg/m2":[347],"q3w":[348],"or":[350,430],"(Rituximab)":[352],"(3":[353],"hours":[354],"infusion)":[355],"combination":[358],"6,":[366],"concentrations":[368],"declined":[371],"steadily":[372],"generally":[375],"bi-phasic":[376],"manner.":[377],"arithmetic":[379],"mean":[380],"\u00b1SD":[381],"(T1/2(hrs);":[385],"Cmax":[386],"(ug/ml);":[387,389],"Cmin":[388],"AUC0-\u221e":[390],"(ug*hrs/ml)":[391],"during":[394],"cycle":[395,397],"1,":[396],"determined.":[403],"All":[404,448],"these":[405],"values":[410,453],"previously":[411,454],"reported":[412,455],"conditions.":[417],"No":[418,474],"anti-drug":[419],"antibody":[420],"case":[421],"reported,":[423],"so":[424],"displaying":[428],"null":[429],"undetectable":[431],"Conclusions:":[433],"indicate":[436],"therapeutic":[438],"levels":[439],"(RTXM83/Mabthera\u00ae)":[442],"observed":[444],"across":[445],"studied":[446],"rituximab.":[457],"Therefore,":[458],"Mabthera\u00ae":[469],"treating":[471],"Disclosures":[473],"relevant":[475],"conflicts":[476],"interest":[478],"declare.":[480]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2016-06-24T00:00:00"}